| 8.08 0.09 (1.13%) | 04-24 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 9.67 | 1-year : | 10.31 |
| Resists | First : | 8.27 | Second : | 8.82 |
| Pivot price | 8.34 |
|||
| Supports | First : | 7.38 | Second : | 6.14 |
| MAs | MA(5) : | 8.26 |
MA(20) : | 8.23 |
| MA(100) : | 8.77 |
MA(250) : | 8.99 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 30.2 |
D(3) : | 45 |
| RSI | RSI(14): 45 |
|||
| 52-week | High : | 10.95 | Low : | 6.78 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ GRFS ] has closed above bottom band by 20.6%. Bollinger Bands are 1.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 8.12 - 8.17 | 8.17 - 8.22 |
| Low: | 7.86 - 7.92 | 7.92 - 7.97 |
| Close: | 8 - 8.09 | 8.09 - 8.17 |
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuumfrom prevention, screening, diagnosis, and prognosis to disease and treatment monitoringto serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.
Sat, 25 Apr 2026
Grifols considers IPO of part of its US biopharma business - MSN
Thu, 23 Apr 2026
Grifols (GRFS) to Release Earnings on Thursday - MarketBeat
Mon, 20 Apr 2026
Grifols, S.A. (GRFS) Stock Analysis: Exploring a 26.86% Upside Potential in the Healthcare Sector - DirectorsTalk Interviews
Fri, 17 Apr 2026
Health Canada Imposes New Conditions on Grifols, S.A. (GRFS) Plasma Collection Centers - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 258 (M) |
| Shares Float | 417 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 57.4 (%) |
| Shares Short | 7,020 (K) |
| Shares Short P.Month | 7,110 (K) |
| EPS | 0.64 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.57 |
| Profit Margin | 5.3 % |
| Operating Margin | 17.5 % |
| Return on Assets (ttm) | 4.2 % |
| Return on Equity (ttm) | 6.1 % |
| Qtrly Rev. Growth | 0.3 % |
| Gross Profit (p.s.) | 11.3 |
| Sales Per Share | 29.12 |
| EBITDA (p.s.) | 6.58 |
| Qtrly Earnings Growth | 43.5 % |
| Operating Cash Flow | 1,050 (M) |
| Levered Free Cash Flow | 1,030 (M) |
| PE Ratio | 12.43 |
| PEG Ratio | 0.1 |
| Price to Book value | 1.76 |
| Price to Sales | 0.27 |
| Price to Cash Flow | 1.98 |
| Dividend | 0.17 |
| Forward Dividend | 0 |
| Dividend Yield | 2.1% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|